Cargando…
Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles
Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579911/ https://www.ncbi.nlm.nih.gov/pubmed/37854883 http://dx.doi.org/10.3389/fbioe.2023.1286502 |
_version_ | 1785121833410887680 |
---|---|
author | Song, Daichen Yang, Xiaofan Chen, Yanfei Hu, Pingping Zhang, Yingying Zhang, Yan Liang, Ning Xie, Jian Qiao, Lili Deng, Guodong Chen, Fangjie Zhang, Jiandong |
author_facet | Song, Daichen Yang, Xiaofan Chen, Yanfei Hu, Pingping Zhang, Yingying Zhang, Yan Liang, Ning Xie, Jian Qiao, Lili Deng, Guodong Chen, Fangjie Zhang, Jiandong |
author_sort | Song, Daichen |
collection | PubMed |
description | Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these challenges and provide more effective and safer options for cancer patients. In recent years, the use of live bacteria, engineered bacteria, or bacterial derivatives to deliver antitumor drugs to specific tumor sites for controlled release has emerged as a promising therapeutic tool. This approach offers several advantages over traditional cancer therapies, including targeted drug delivery and reduced toxicity to healthy tissues. Ongoing research in this field holds great potential for further developing more efficient and personalized cancer therapies, such as E. coli, Salmonella, Listeria, and bacterial derivatives like outer membrane vesicles (OMVs), which can serve as vehicles for drugs, therapeutic proteins, or antigens. In this review, we describe the advances, challenges, and future directions of research on using live bacteria or OMVs as carriers or components derived from bacteria of delivery systems for cancer therapy. |
format | Online Article Text |
id | pubmed-10579911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105799112023-10-18 Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles Song, Daichen Yang, Xiaofan Chen, Yanfei Hu, Pingping Zhang, Yingying Zhang, Yan Liang, Ning Xie, Jian Qiao, Lili Deng, Guodong Chen, Fangjie Zhang, Jiandong Front Bioeng Biotechnol Bioengineering and Biotechnology Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these challenges and provide more effective and safer options for cancer patients. In recent years, the use of live bacteria, engineered bacteria, or bacterial derivatives to deliver antitumor drugs to specific tumor sites for controlled release has emerged as a promising therapeutic tool. This approach offers several advantages over traditional cancer therapies, including targeted drug delivery and reduced toxicity to healthy tissues. Ongoing research in this field holds great potential for further developing more efficient and personalized cancer therapies, such as E. coli, Salmonella, Listeria, and bacterial derivatives like outer membrane vesicles (OMVs), which can serve as vehicles for drugs, therapeutic proteins, or antigens. In this review, we describe the advances, challenges, and future directions of research on using live bacteria or OMVs as carriers or components derived from bacteria of delivery systems for cancer therapy. Frontiers Media S.A. 2023-10-03 /pmc/articles/PMC10579911/ /pubmed/37854883 http://dx.doi.org/10.3389/fbioe.2023.1286502 Text en Copyright © 2023 Song, Yang, Chen, Hu, Zhang, Zhang, Liang, Xie, Qiao, Deng, Chen and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Song, Daichen Yang, Xiaofan Chen, Yanfei Hu, Pingping Zhang, Yingying Zhang, Yan Liang, Ning Xie, Jian Qiao, Lili Deng, Guodong Chen, Fangjie Zhang, Jiandong Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles |
title | Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles |
title_full | Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles |
title_fullStr | Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles |
title_full_unstemmed | Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles |
title_short | Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles |
title_sort | advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579911/ https://www.ncbi.nlm.nih.gov/pubmed/37854883 http://dx.doi.org/10.3389/fbioe.2023.1286502 |
work_keys_str_mv | AT songdaichen advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT yangxiaofan advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT chenyanfei advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT hupingping advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT zhangyingying advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT zhangyan advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT liangning advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT xiejian advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT qiaolili advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT dengguodong advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT chenfangjie advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles AT zhangjiandong advancesinantitumorbasedonvariousanaerobicbacteriaandtheirderivativesasdrugvehicles |